Regeneron CEO: Amgen’s disruptive Praluent-blocking patent move hurts patients
From the article:
Now, Regeneron and Sanofi will ask the Federal Circuit “to quickly review if we can have a stay, and frankly, the merits of the entire case as quickly as possible,” Schleifer said.
Schleifer isn't alone in his criticism. Legal experts have questioned not just the ruling, but Amgen's decision to ask for it. In Harvard Law School's Bill of Health Blog, Rachel Sachs, an associate professor at the Washington University in St. Louis School of Law, echoed Schleifer in pointing out that the injunction, if it takes effect, will push current Praluent patients off the drug, and, given payer exclusives, disrupt insurance coverage.
"Judge Robinson looked at a situation involving two competing, chemically distinct (though similar) drugs for the same condition and opted to kick one of them off the market," Sachs said, "putting Amgen in a monopoly position and taking some number of patients off of the drug they’ve been taking."
Read the full article here.health law policy innovation pharmaceuticals rachel sachs regulation